Detection and removal of melanoma, before it has metastasized, dramatically improves prognosis and survival.
Shanghai Junshi Biosciences announced that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy.
The China National Medical Products Administration (NMPA) has approved KeChow Pharma’s tunlametinib (HL 085) for treating patients with neuroblastoma ras viral oncogene homolog (NRAS) mutated advanced melanoma.
In a provisional draft guidance the National Institute for Health and Clinical Excellence (NICE)will not recommend payment by the UK...
Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape...
Prior to 2011, the 1-year survival rates for patients suffering from advanced or metastatic melanoma was as low as 33%, with a median overall survival of about 9 months.
Areas covered: This is a comprehensive review of the literature on the role of pembrolizumab in melanoma.
Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations.
Genmab announced that the European Commission (EC) has granted a conditional marketing authorization for CD38 antibody Darzalex (daratumumab). The conditional...
We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations.